Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2012 1
2013 1
2015 2
2016 3
2017 1
2018 5
2019 7
2020 15
2021 27
2022 25
2023 31
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

123 results

Results by year

Filters applied: . Clear all
Page 1
Setmelanotide: First Approval.
Markham A. Markham A. Drugs. 2021 Feb;81(3):397-403. doi: 10.1007/s40265-021-01470-9. Drugs. 2021. PMID: 33638809 Review.
Setmelanotide (IMCIVREE, Rhythm Pharmaceuticals) is a melanocortin-4 (MC4) receptor agonist developed for the treatment of obesity arising from proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency. ...This …
Setmelanotide (IMCIVREE, Rhythm Pharmaceuticals) is a melanocortin-4 (MC4) receptor agonist developed for the treatment of obesity ar …
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alstrom syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period.
Haqq AM, Chung WK, Dollfus H, Haws RM, Martos-Moreno GÁ, Poitou C, Yanovski JA, Mittleman RS, Yuan G, Forsythe E, Clément K, Argente J. Haqq AM, et al. Lancet Diabetes Endocrinol. 2022 Dec;10(12):859-868. doi: 10.1016/S2213-8587(22)00277-7. Epub 2022 Nov 7. Lancet Diabetes Endocrinol. 2022. PMID: 36356613 Free PMC article. Clinical Trial.
Patients were randomly assigned (1:1) using a numerical randomisation code to receive up to 3.0 mg of subcutaneous setmelanotide or placebo once per day during the 14-week double-blind period, followed by open-label setmelanotide for 52 weeks. ...Two patients had fo …
Patients were randomly assigned (1:1) using a numerical randomisation code to receive up to 3.0 mg of subcutaneous setmelanotide or p …
Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?
Ryan DH. Ryan DH. J Obes Metab Syndr. 2021 Sep 30;30(3):196-208. doi: 10.7570/jomes21033. J Obes Metab Syndr. 2021. PMID: 34518444 Free PMC article. Review.
There is a new generation of antiobesity drugs in development or just arriving on the scene. First, setmelanotide has been approved for three of the ultrarare genetic conditions that cause obesity-pro-opiomelanocortin deficiency, proprotein convertase subtilisin and kexin …
There is a new generation of antiobesity drugs in development or just arriving on the scene. First, setmelanotide has been approved f …
Setmelanotide: A Novel Targeted Treatment for Monogenic Obesity.
Pressley H, Cornelio CK, Adams EN. Pressley H, et al. J Pharm Technol. 2022 Dec;38(6):368-373. doi: 10.1177/87551225221116010. Epub 2022 Aug 30. J Pharm Technol. 2022. PMID: 36311304 Free PMC article. Review.
Data Sources: A literature review was performed by searching MEDLINE, SCOPUS, and EMBASE for all relevant English-language articles published between January 1, 1996, and November 30, 2021, using search terms obesity, setmelanotide, Imcivree, and MC4R agonist. Study Select …
Data Sources: A literature review was performed by searching MEDLINE, SCOPUS, and EMBASE for all relevant English-language articles publishe …
Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.
Collet TH, Dubern B, Mokrosinski J, Connors H, Keogh JM, Mendes de Oliveira E, Henning E, Poitou-Bernert C, Oppert JM, Tounian P, Marchelli F, Alili R, Le Beyec J, Pépin D, Lacorte JM, Gottesdiener A, Bounds R, Sharma S, Folster C, Henderson B, O'Rahilly S, Stoner E, Gottesdiener K, Panaro BL, Cone RD, Clément K, Farooqi IS, Van der Ploeg LHT. Collet TH, et al. Mol Metab. 2017 Oct;6(10):1321-1329. doi: 10.1016/j.molmet.2017.06.015. Epub 2017 Jul 8. Mol Metab. 2017. PMID: 29031731 Free PMC article. Clinical Trial.
While POMC deficiency is very rare, 1-5% of severely obese individuals harbor heterozygous mutations in MC4R. We sought to assess the efficacy of Setmelanotide in human MC4R deficiency. METHODS: We studied the effects of Setmelanotide on mutant MC4Rs in cells and th …
While POMC deficiency is very rare, 1-5% of severely obese individuals harbor heterozygous mutations in MC4R. We sought to assess the effica …
Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity.
Trapp CM, Censani M. Trapp CM, et al. Curr Opin Endocrinol Diabetes Obes. 2023 Apr 1;30(2):136-140. doi: 10.1097/MED.0000000000000798. Epub 2023 Feb 1. Curr Opin Endocrinol Diabetes Obes. 2023. PMID: 36722447 Free PMC article. Review.
PURPOSE OF REVIEW: Examine Setmelanotide use in patients with rare genetic variants that disrupt the melanocortin pathway. ...As a result, Setmelanotide was approved by the U.S. FDA in 2020 for chronic weight management in adult and pediatric patients 6 years of age …
PURPOSE OF REVIEW: Examine Setmelanotide use in patients with rare genetic variants that disrupt the melanocortin pathway. ...As a re …
Setmelanotide.
Hussain A, Farzam K. Hussain A, et al. 2023 Jul 2. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Jul 2. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 36943959 Free Books & Documents.
Setmelanotide is a medication that acts on the melanocortin-4 receptor (MC4R) for the treatment of severe obesity caused by genetic disorders, including deficiency of proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEP …
Setmelanotide is a medication that acts on the melanocortin-4 receptor (MC4R) for the treatment of severe obesity caused by genetic d …
Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
Clément K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, De Waele K, Farooqi IS, Gonneau-Lejeune J, Gordon G, Kohlsdorf K, Poitou C, Puder L, Swain J, Stewart M, Yuan G, Wabitsch M, Kühnen P; Setmelanotide POMC and LEPR Phase 3 Trial Investigators. Clément K, et al. Lancet Diabetes Endocrinol. 2020 Dec;8(12):960-970. doi: 10.1016/S2213-8587(20)30364-8. Epub 2020 Oct 30. Lancet Diabetes Endocrinol. 2020. PMID: 33137293 Clinical Trial.
Participants aged 6 years or older with POMC or LEPR deficiency obesity received open-label setmelanotide for 12 weeks. Participants with at least 5 kg weight loss (or 5% if weighing <100 kg at baseline) entered an 8-week placebo-controlled withdrawal sequence (includin …
Participants aged 6 years or older with POMC or LEPR deficiency obesity received open-label setmelanotide for 12 weeks. Participants …
Setmelanotide Acetate.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 2021 Mar 31;78(8):652-655. doi: 10.1093/ajhp/zxab093. Am J Health Syst Pharm. 2021. PMID: 33787829 No abstract available.
123 results

Searches related to "setmelanotide"